Time to CA19.9 nadir: a clue for defining treatment duration of primary chemotherapy in resectable PDAC

Introduction: We analyzed time to CA19-9 nadir during first-line chemotherapy in patients with metastatic, unresectable, and borderline resectable pancreatic ductal adenocarcinoma (PDAC) to investigate the relationship between biomarker response and duration of chemotherapy Methods: We analyzed data of PDAC patients with elevated CA19-9 baseline levels who received ≥4 months chemotherapy from the databases of prospective trials conducted at our...